Nkarta, Inc. (NASDAQ:NKTX) Receives $10.75 Average PT from Analysts

Posted by Brenda Bartman on Aug 14th, 2026

Shares of Nkarta, Inc. (NASDAQ:NKTX – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the seven research firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $11.40.

Several research firms have recently weighed in on NKTX. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price objective on shares of Nkarta in a report on Wednesday, May 13th. TD Cowen started coverage on Nkarta in a research note on Tuesday, June 23rd. They set a “buy” rating for the company. Wall Street Zen upgraded shares of Nkarta from a “strong sell” rating to a “sell” rating in a report on Sunday, August 2nd. HC Wainwright cut their price target on shares of Nkarta to $14.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Evercore set a $9.00 price target on shares of Nkarta in a report on Monday, May 18th.

View Our Latest Stock Report on Nkarta

Nkarta Trading Down 3.8%

Nkarta stock opened at $2.30 on Friday. The company has a market cap of $164.73 million, a PE ratio of -1.46 and a beta of 0.93. Nkarta has a 1 year low of $1.70 and a 1 year high of $3.72. The company’s 50-day moving average is $2.64 and its two-hundred day moving average is $2.58.

Nkarta (NASDAQ:NKTX – Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.18). Research analysts forecast that Nkarta will post -1.51 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in NKTX. Forefront Analytics LLC bought a new position in shares of Nkarta in the second quarter valued at $82,000. Ieq Capital LLC bought a new stake in Nkarta during the second quarter worth $501,000. BlackRock Inc. acquired a new stake in Nkarta in the second quarter valued at $17,830,000. Pallas Capital Advisors LLC bought a new position in shares of Nkarta in the 2nd quarter valued at about $31,000. Finally, Deutsche Bank AG bought a new position in shares of Nkarta in the 2nd quarter valued at about $129,000. Institutional investors and hedge funds own 80.54% of the company’s stock.

About Nkarta

(Get Free Report)

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.